← Back to patent-cliff list
LY-356318
Tier C — Watch / tradeLY-356318
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TRPA1
Indications (approved)：Osteoarthritis, Knee arthritis
Regional status
US
Phase II
2021-10-12
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-356318?
Approved indications include: Osteoarthritis, Knee arthritis.
When does the LY-356318 patent expire?
No public expiry year is available for LY-356318 yet; this page updates once verified.
How do I get a quote for LY-356318 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06